A-1210477

製品コードS7790 バッチS779002

印刷

化学情報

 Chemical Structure Synonyms N/A Storage
(From the date of receipt)
3 years -20°C powder
1 years -80°C in solvent
化学式

C46H55N7O7S

分子量 850.04 CAS No. 1668553-26-1
Solubility (25°C)* 体外 DMSO (warmed with 50ºC water bath) 3 mg/mL (3.52 mM)
Water Insoluble
Ethanol Insoluble
体内 (毎回新しく調製した物を用意してください)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O

この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。

0.150mg/ml (0.18mM) Taking the 1 mL working solution as an example, add 50 μL of 3 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil

この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。

0.150mg/ml (0.18mM) Taking the 1 mL working solution as an example, add 50 μL of 3 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液(一定の濃度)を調合する

生物活性

製品説明 A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
in vitro In H929 cells, A-1210477 binds to MCL-1 with high affinity and induces MCL-1 protein elevation. In H929, H2110, and H23 cells, this compound induces the hallmarks of apoptosis, and inhibits MCL-1-dependent cell viability. It also synergizes with navitoclax to kill a variety of cancer cell lines. [1] In SKBR3 cells, this chemical inhibits MCL-1–BIM interaction and induces classical features of apoptosis. [2] In addition, it sensitizes non-Hodgkin's lymphoma cell lines to venetoclax (ABT-199). [3]

プロトコル(参考用のみ)

キナーゼアッセイ Binding affinity assays
TR-FRET-binding affinity assays are performed for BCL-2, BCL-XL, and MCL-1 in 4.52 mM monobasic potassium phosphate, 15.48 mM dibasic potassium phosphate, 1 mM sodium EDTA, 0.05% Pluronic F-68 detergent, 50 mM sodium chloride, and 1 mM DTT (pH 7.5). For MCL-1 assays, GST-tagged MCL-1 (1 nM) is mixed with 100 nM f-Bak, 1 nM Tb-labeled anti-GST antibody, and this compound at room temperature (RT) for 60 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-GST antibody) emission filters.
細胞アッセイ 細胞株 H929, H2110, and H23 cells
濃度 ~30 μM
反応時間 48 h or 72 h
実験の流れ Adherent cell lines are seeded at 50 000 cells per well in 96-well plates and treated for 48 h with compounds diluted in half-log steps starting at 30 μM and ending at 0.001 μM. Multiple myeloma cell lines were seeded at 15 000–20 000 cells per well and treated similarly. Effects on proliferation and viability were determined using CellTiter-Glo reagent according to the manufacturer’s instructions. IC50 values are determined by non-linear regression analysis of the concentration response data.

参考

  • https://pubmed.ncbi.nlm.nih.gov/25590800/
  • https://pubmed.ncbi.nlm.nih.gov/26013319/
  • https://pubmed.ncbi.nlm.nih.gov/26565405/

カスタマーフィードバック

Data from [Data independently produced by , , Cancer Research, 2017, doi:10.1158/0008-5472]

Data from [Data independently produced by , , Cell Death Dis, 2018, 9(9):907]

Data from [Data independently produced by , , Cell Death Dis, 2016, 7(8):e2340. ]

Selleckの高級品が、幾つかの出版された研究調査結果(以下を含む)で使われた:

20(S)-protopanaxadiol inhibits proliferation and induces apoptosis of acute myeloid leukemia cells via targeting Bcl-XL and MCL-1 [ Front Pharmacol, 2025, 16:1530270] PubMed: 40400713
Targeting MCL-1 triggers DNA damage and an anti-proliferative response independent from apoptosis induction [ Cell Rep, 2023, 42(10):113176] PubMed: 37773750
MCL1 Inhibition Overcomes the Aggressiveness Features of Triple-Negative Breast Cancer MDA-MB-231 Cells [ Int J Mol Sci, 2023, 24(13)11149] PubMed: 37446326
MCL1 Inhibition Overcomes the Aggressiveness Features of Triple-Negative Breast Cancer MDA-MB-231 Cells [ Int J Mol Sci, 2023, 24(13)11149] PubMed: 37446326
Serum level of apoptosis inhibitor of macrophage in dogs with histiocytic sarcoma and its association with the disease [ Vet Comp Oncol, 2023, 10.1111/vco.12897] PubMed: 37088561
The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and Aurora kinases [ Res Sq, 2023, rs.3.rs-2570204] PubMed: 36865133
Der BCL-2 Inhibitor ABT-199/Venetoclax transaktiviert NOXA und wirkt mit Proteasom-Inhibition bei der Zelltod-Induktion synergistisch [ University of Tübingen, 2023, 10.15496/publikation-82336] PubMed: None
Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies [ Blood, 2022, blood.2021014304] PubMed: 35704690
Novel roles of RTN4 and CLIMP-63 in regulating mitochondrial structure, bioenergetics and apoptosis [ Cell Death Dis, 2022, 13(5):436] PubMed: 35508606
BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment [ Cell Death Dis, 2021, 12(8):736] PubMed: 34312366

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。